var data={"title":"Management of refractory pemphigus vulgaris and pemphigus foliaceus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Management of refractory pemphigus vulgaris and pemphigus foliaceus</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/contributors\" class=\"contributor contributor_credentials\">Michael Hertl, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/contributors\" class=\"contributor contributor_credentials\">R&uuml;diger Eming, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/contributors\" class=\"contributor contributor_credentials\">John J Zone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 20, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H13593182\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pemphigus vulgaris and pemphigus foliaceus are autoimmune blistering diseases that may result in significant morbidity and death. First-line treatment for pemphigus consists of systemic immunosuppression with systemic glucocorticoids with or without adjuvant immunosuppressive medications [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/1-3\" class=\"abstract_t\">1-3</a>]. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;</a> and <a href=\"topic.htm?path=initial-management-of-pemphigus-vulgaris-and-pemphigus-foliaceus\" class=\"medical medical_review\">&quot;Initial management of pemphigus vulgaris and pemphigus foliaceus&quot;</a>.) </p><p>Patients who do not respond to first-line therapies may benefit from additional interventions. Treatment regimens that include <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG), immunoadsorption, plasmapheresis, and <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> may lead to clinical improvement in these patients. </p><p>The treatment of pemphigus vulgaris and pemphigus foliaceus refractory to initial therapies will be reviewed here. The initial management of pemphigus vulgaris and pemphigus foliaceus, and the management of paraneoplastic pemphigus are reviewed separately. (See <a href=\"topic.htm?path=initial-management-of-pemphigus-vulgaris-and-pemphigus-foliaceus\" class=\"medical medical_review\">&quot;Initial management of pemphigus vulgaris and pemphigus foliaceus&quot;</a> and <a href=\"topic.htm?path=paraneoplastic-pemphigus#H7465430\" class=\"medical medical_review\">&quot;Paraneoplastic pemphigus&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H255874776\"><span class=\"h1\">DEFINITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The initial approach to the treatment of pemphigus vulgaris and pemphigus foliaceus consists of systemic glucocorticoid therapy, which is often given in conjunction with an adjuvant nonsteroidal immunosuppressant, such as <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> or <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil. The term refractory pemphigus is generally used to refer to pemphigus that fails to respond sufficiently to optimal administration of these agents. The initial management of pemphigus is reviewed in detail separately. (See <a href=\"topic.htm?path=initial-management-of-pemphigus-vulgaris-and-pemphigus-foliaceus\" class=\"medical medical_review\">&quot;Initial management of pemphigus vulgaris and pemphigus foliaceus&quot;</a>.)</p><p>Various definitions for refractory pemphigus have been utilized in the medical literature. In 2008, a panel of experts proposed standardized definitions for the assessment of therapeutic responses in pemphigus for use in clinical studies, including definitions of treatment failure from certain therapies [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/4\" class=\"abstract_t\">4</a>]. The consistent use of these guidelines in clinical studies may facilitate systematic interpretation of the literature in the future and may provide further clarification on therapeutic efficacy.</p><p class=\"headingAnchor\" id=\"H13593189\"><span class=\"h1\">OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pemphigus is a chronic disorder that usually requires treatment for a period of years. A retrospective study of 40 patients with pemphigus vulgaris who were seen in an academic medical center between 1983 and 1993 and followed for an average of 7.7 years found that long-lasting complete remission (ie, complete clinical remission off systemic therapy for at least six months) was achieved in 25 percent after 2 years, 50 percent after 5 years, and 75 percent after 10 years [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/5\" class=\"abstract_t\">5</a>]. </p><p>Although the majority of patients with pemphigus vulgaris or pemphigus foliaceus (around 60 to 80 percent) can achieve at least initial improvement with first-line therapies [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/6-8\" class=\"abstract_t\">6-8</a>], other patients fail to respond or experience frequent relapses while on these therapies. Our first steps for patients who fail initial therapy are to optimize the dose of the systemic glucocorticoid (up to a maximum of an equivalent of 1.5 to 2 <span class=\"nowrap\">mg/kg</span> per day of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>) and adjuvant agent, or to change the adjuvant therapy to a different first-line agent (eg, change from <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> to <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil or vice versa). If an adequate response still cannot be obtained, we proceed with the initiation of other therapies. </p><p>The major therapeutic options for refractory disease include interventions that directly target the antibody-mediated pathogenesis of pemphigus (<a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> [IVIG], immunoadsorption, and plasmapheresis) and <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, a drug that may be used as an alternative adjuvant immunosuppressant. Concern for the high cost of rituximab, IVIG, immunoadsorption, and plasmapheresis and the unfavorable adverse effect profile of cyclophosphamide (eg, sterility, cytopenia, hemorrhagic cystitis) contribute to the preferred use of these agents for refractory pemphigus, rather than for new-onset disease.</p><p>In addition to patients who fail to respond to first-line regimens, other patients with pemphigus may benefit from the therapies utilized for refractory disease. Patients with contraindications to initial therapies or who are unable to tolerate initial treatments may also benefit from treatments used for refractory disease.</p><p class=\"headingAnchor\" id=\"H36962895\"><span class=\"h1\">TREATMENT OPTIONS</span></p><p class=\"headingAnchor\" id=\"H7885644\"><span class=\"h2\">Treatment selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The paucity of high-quality studies on the treatment of refractory pemphigus impedes both conclusions on the relative efficacies of interventions as well as the formation of definitive guidelines on the best approach to the treatment [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/9\" class=\"abstract_t\">9</a>]. Thus, therapeutic choice remains heavily influenced by consideration of patient tolerability for specific treatments and treatment availability. In particular, treatment-specific contraindications should be considered.</p><p>Examples of clinical scenarios that have influenced the choice of therapy for our patients include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preference to avoid <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> in a patient of child-bearing potential due to the risk of cyclophosphamide-induced premature gonadal failure</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preference to avoid extracorporeal therapies such as immunoadsorption and plasmapheresis in older patients with severe heart disease</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preference for use of a rapid-acting therapy (eg, immunoadsorption) in patients with severe manifestations of the disease</p><p/><p>Treatment availability is a major factor in treatment selection that is based on both the ability to obtain a treatment and access to appropriate equipment and expertise to administer it safely. For example, although the use of <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> for refractory pemphigus has decreased in clinical settings where patients have access to other less toxic treatment options, the relatively higher cost and more limited availability of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG), immunoadsorption, and plasmapheresis contributes to the continued use of cyclophosphamide in certain clinical settings. Whenever possible, the therapies utilized for refractory pemphigus should be administered by clinicians experienced in the use and adverse effects of these treatments. Referral to specialized treatment centers can be useful for additional access to treatments.</p><p>We manage most patients with refractory pemphigus with the addition of one of the therapeutic options for refractory pemphigus to baseline immunosuppressive regimen that consists of systemic glucocorticoids with or without a first-line adjuvant medication. Although combination therapy with immunoadsorption and <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> has been utilized by ourselves and other clinicians for patients with severe, refractory disease (extensive involvement or involvement of mucosal sites that may result in significant morbidity [conjunctiva, pharynx, larynx, or esophagus]), additional studies are necessary to confirm whether this approach is ideal. (See <a href=\"#H36961953\" class=\"local\">'Combination therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H13593210\"><span class=\"h2\">Rituximab</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon the rationale that pemphigus is primarily an autoantibody-driven autoimmune disorder, therapies that deplete autoreactive B cell clones have been investigated for the treatment of pemphigus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/10,11\" class=\"abstract_t\">10,11</a>]. <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">Rituximab</a>, a monoclonal antibody directed against the CD20 antigen on B lymphocytes, has demonstrated efficacy for pemphigus vulgaris and pemphigus foliaceus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/12-14\" class=\"abstract_t\">12-14</a>]. The immunologic effects of rituximab that contribute to its benefit in pemphigus may be complex; long-lasting B-cell depletion following rituximab treatment may be one significant factor [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/15-17\" class=\"abstract_t\">15-17</a>]. Additional findings during rituximab therapy that may be involved in the treatment effect include a preferential decline in autoantibodies compared with pathogen-specific antibodies (potentially due to a different effect of rituximab on autoreactive and pathogen-specific plasma cells) and a decline in autoreactive CD4<sup>+</sup> T cells (a possible indirect effect of B cell depletion) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/15,16\" class=\"abstract_t\">15,16</a>]. </p><p class=\"headingAnchor\" id=\"H255875039\"><span class=\"h3\">Efficacy and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following initial reports of the positive impact of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> on paraneoplastic pemphigus in patients treated with rituximab for B-cell lymphoma [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/18,19\" class=\"abstract_t\">18,19</a>], multiple uncontrolled studies and case series have supported the efficacy of rituximab in patients with pemphigus vulgaris and pemphigus foliaceus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/11,20\" class=\"abstract_t\">11,20</a>]. In accordance with the emergence of rituximab therapy for pemphigus from patients with lymphoma [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/18,19\" class=\"abstract_t\">18,19</a>], dosing for rituximab in pemphigus initially reflected a regimen commonly used for lymphoma (375 <span class=\"nowrap\">mg/m<sup>2</sup></span> once weekly for four weeks) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/21\" class=\"abstract_t\">21</a>]. Since then, other dose regimens for rituximab have been evaluated in clinical studies [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/22-25\" class=\"abstract_t\">22-25</a>]. Most often, a dose regimen similar to that used in the treatment of rheumatologic disease (two 1000 mg infusions separated by two weeks) is given. Lower dose regimens (eg, two 500 mg doses of rituximab separated by two weeks) may be associated with reduced duration of remission. (See <a href=\"#H36961921\" class=\"local\">'Rheumatologic dosing'</a> below and <a href=\"#H2495368859\" class=\"local\">'Lymphoma dosing'</a> below and <a href=\"#H36961939\" class=\"local\">'Other protocols'</a> below.)</p><p class=\"headingAnchor\" id=\"H36961921\"><span class=\"h4\">Rheumatologic dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">Rituximab</a> also appears to be effective for pemphigus when administered in a regimen similar to the regimen used for rheumatoid arthritis (two 1000 mg infusion separated by two weeks) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/22-24,26\" class=\"abstract_t\">22-24,26</a>]. Advantages of this dose over lymphoma dosing include the requirement for fewer infusion sessions and the often lower total dose of rituximab required for treatment.</p><p>One of the largest prospective studies to evaluate the treatment of refractory pemphigus with this protocol is a study of 42 patients with severe refractory pemphigus vulgaris (n = 37) or pemphigus foliaceus (n = 5) in which patients were treated with <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> and <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (0.5 <span class=\"nowrap\">mg/kg</span> per day followed by a taper to discontinuation) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/27\" class=\"abstract_t\">27</a>]. After six months, complete remission (defined as an absence of new or established lesions) occurred in 36 patients (86 percent), including 29 patients who had complete remissions for at least two months after treatment was stopped and seven patients who required minimal therapy (&le;10 mg per day of prednisone for at least two months). </p><p>The median time to complete remission was 70 days (range 30 to 150 days). The seven patients who required minimal therapy were able to discontinue treatment within three additional months. An additional 500 mg dose of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> led to complete remissions in the six patients who had partial remissions and to reinstitution of complete remission in 20 patients who relapsed. The median time to relapse was 16 months (range 6 to 41 months). Additional doses of rituximab also appeared to be of benefit for patients who relapsed or failed to achieve remission after a single cycle of rituximab in a retrospective study of 92 patients with pemphigus vulgaris or pemphigus foliaceus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/26\" class=\"abstract_t\">26</a>].</p><p>Rheumatologic dosing of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> given in combination with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> has been evaluated as an initial therapy for pemphigus. The use of rituximab as initial therapy is reviewed separately. (See <a href=\"topic.htm?path=initial-management-of-pemphigus-vulgaris-and-pemphigus-foliaceus#H3287220404\" class=\"medical medical_review\">&quot;Initial management of pemphigus vulgaris and pemphigus foliaceus&quot;, section on 'Alternative first-line therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H2495368859\"><span class=\"h4\">Lymphoma dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Uncontrolled studies and case series support a beneficial effect of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> given in a dose of 375 <span class=\"nowrap\">mg/m<sup>2</sup></span> in various regimens [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/11\" class=\"abstract_t\">11</a>]. The benefit of a single cycle of rituximab (375 <span class=\"nowrap\">mg/m<sup>2</sup></span> once weekly for four weeks) was illustrated in an open, multicenter study of 14 patients with pemphigus and 7 patients with pemphigus foliaceus. The patients had disease that was refractory to systemic glucocorticoids, had experienced multiple relapses during glucocorticoid tapering, or were unable to receive systemic glucocorticoids due to contraindications to glucocorticoid therapy [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/28\" class=\"abstract_t\">28</a>]. The treatment protocol consisted of rituximab and a systemic glucocorticoid that was tapered as tolerated. Five patients did not receive a systemic glucocorticoid due to contraindications for glucocorticoid therapy. </p><p>Of the 21 patients, 18 (86 percent) achieved complete remission (defined as epithelialization of all lesions) within three months. The median time to complete remission for cutaneous pemphigus vulgaris, mucosal pemphigus vulgaris, and pemphigus foliaceus were 30, 90, and 60 days, respectively. Two additional patients achieved complete remission within six months and one year. Although nine of the patients who achieved complete remission relapsed during the course of the study within a mean of 19 months, seven of these patients were successfully managed with topical or systemic glucocorticoids, and the remaining two responded to a second course of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>. </p><p>The number of treatments administered with this dose of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> may influence patient outcomes. A retrospective analysis of 27 patients found that three or more infusions of rituximab (375 <span class=\"nowrap\">mg/m<sup>2</sup></span> once weekly) was associated with better patient outcomes than fewer treatments [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/29\" class=\"abstract_t\">29</a>]. </p><p>Additional doses of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> after completion of an initial treatment cycle are typically reserved for patients who relapse or do not respond adequately to therapy. The findings of a nonrandomized prospective study of 17 patients treated for pemphigus with 375 <span class=\"nowrap\">mg/m<sup>2</sup></span> of rituximab once weekly for four weeks suggest that a prophylactic infusion of rituximab six months after treatment may not be of benefit [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H36961939\"><span class=\"h4\">Other protocols</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">Rituximab</a> administered in a lower dose than described above may be effective for pemphigus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/25,31\" class=\"abstract_t\">25,31</a>] though further study is necessary to clarify whether long-term outcomes are less favorable when compared with outcomes from higher dose regimens [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/25,31,32\" class=\"abstract_t\">25,31,32</a>]. The comparative efficacy of low-dose rituximab (two 500 mg doses of rituximab separated by two weeks) and standard rheumatologic dosing of rituximab (two 1000 mg infusions separated by two weeks) was evaluated in a 48-week randomized trial with 22 patients with pemphigus vulgaris or pemphigus foliaceus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/31\" class=\"abstract_t\">31</a>]. The study population included both patients who had failed other therapies and patients who received rituximab as initial treatment. Most patients received systemic glucocorticoids in addition to rituximab and adjuvant immunosuppressants (primarily <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>) were added for patients with incomplete responses to treatment.</p><p>All 11 patients in the low-dose <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> group and 10 of 11 patients in the standard rheumatologic dosing group achieved complete remission. Although the trial did not find statistically significant differences in the primary endpoints (time to disease control, time to end of consolidation phase, time to partial remission, or time to complete remission) between the two groups, there was a non-statistically significant trend towards greater risk for relapse among patients treated with low-dose rituximab than among patients given the rheumatologic dose regimen (64 versus 36 percent relapsed, respectively). In addition, patients in the low-dose rituximab group had a significantly higher cumulative dose of <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, and a statistically significant decline in enzyme-linked immunosorbent assay (ELISA) indices of desmoglein 1 and desmoglein 3 was evident only in the rheumatologic dose group. </p><p>Limited data suggest that intralesional injection of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> may be an effective treatment modality for oral pemphigus. In an open study, all of three patients given intralesional rituximab (5 <span class=\"nowrap\">mg/cm<sup>2</sup></span> on days 1 and 15) for refractory oral pemphigus vulgaris had marked improvement [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/33\" class=\"abstract_t\">33</a>]. One patient achieved clinical remission of oral lesions at week 12 and the remaining two patients achieved clinical remission at week 16. Adverse effects were limited to pain from injection in one patient. Of note, marked reductions in peripheral blood CD19<sup>+</sup> B cell counts were noted in all patients two weeks after the initial treatment session. Patients were followed for up to six months; one patient relapsed five months after the start of therapy. Further study is necessary to confirm the efficacy of this therapy.</p><p class=\"headingAnchor\" id=\"H469929829\"><span class=\"h4\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pemphigus is rare in children and data on <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> therapy for pemphigus in this population are limited [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/34,35\" class=\"abstract_t\">34,35</a>]. The findings of a retrospective study of 10 children (&lt;18 years of age) who had severe or resistant pemphigus or who were unable to tolerate other treatments support a beneficial effect of rituximab in children. The study evaluated outcomes after treatment with rituximab (either two 500 mg doses of rituximab separated by 15 days or two 375 <span class=\"nowrap\">mg/m<sup>2</sup></span> doses of rituximab separated by 15 days) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/34\" class=\"abstract_t\">34</a>]. All 10 children improved after rituximab therapy, including 7 children who achieved complete remission off all therapy after a single infusion cycle. The mean time to complete remission was 21 weeks. Six children experienced relapses, with a mean time to relapse of 13 months. Two of the children who relapsed were subsequently given rituximab and both achieved good results. Further study is needed to confirm the safety and efficacy of rituximab for pemphigus in children.</p><p class=\"headingAnchor\" id=\"H36961953\"><span class=\"h4\">Combination therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">Rituximab</a> has been combined with IVIG or immunoadsorption in attempts to take advantage of the fast onset of action of these therapies [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/36-40\" class=\"abstract_t\">36-40</a>]. Although rapid and long-lasting remissions have been reported in uncontrolled studies of patients with refractory pemphigus who were treated with combination therapy [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/36-40\" class=\"abstract_t\">36-40</a>], the efficacy of rituximab given with and without these therapies has not been directly compared. Examples of studies that have evaluated combination therapy are provided:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an uncontrolled study of 11 patients with refractory pemphigus vulgaris, combination therapy with <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> and IVIG was associated with rapid resolution of lesions and sustained clinical remissions in nine patients [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/36\" class=\"abstract_t\">36</a>]. The remaining two patients relapsed after initial therapy, but achieved sustained remissions following one or two additional courses of rituximab. Among the 10 patients available for a 10-year follow-up study (follow-up range of 111 to 136 months), all remained in remission without recurrence of disease. [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/40\" class=\"abstract_t\">40</a>]. Pemphigus IgG autoantibodies remained undetectable in serum during the 10-year follow-up period.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of 23 patients with severe pemphigus treated with immunoadsorption, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, pulsed <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, and <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> or <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil, improvement in pemphigus was noted within a few weeks and 19 patients (83 percent) achieved long-term complete remissions [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/37\" class=\"abstract_t\">37</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study of 10 patients with refractory pemphigus vulgaris, eight patients achieved complete remission within six months after the addition of immunoadsorption and <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> to systemic glucocorticoids <span class=\"nowrap\">and/or</span> glucocorticoid sparing agents [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/38\" class=\"abstract_t\">38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an uncontrolled study of seven patients with severe or refractory pemphigus treated with immunoadsorption, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, and conventional immunosuppressants with or without IVIG, all patients had improvement in clinical manifestations within four weeks and three patients achieved long-term remissions [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/39\" class=\"abstract_t\">39</a>].</p><p/><p class=\"headingAnchor\" id=\"H341812094\"><span class=\"h3\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although serious infections have been reported in patients treated with <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> for pemphigus, the effect of rituximab on risk for infections is unclear because of the concomitant use of other immunosuppressive drugs [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/11\" class=\"abstract_t\">11</a>]. A 2009 review of 136 patients treated with rituximab for pemphigus found that severe infections were reported in about 10 percent of patients and fatal infectious events occurred in 3 percent of patients [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/11\" class=\"abstract_t\">11</a>]. Of note, progressive multifocal leukoencephalopathy has been reported in patients treated with rituximab for other indications [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/41,42\" class=\"abstract_t\">41,42</a>]. (See <a href=\"topic.htm?path=rituximab-and-other-b-cell-targeted-therapies-for-rheumatoid-arthritis#H16\" class=\"medical medical_review\">&quot;Rituximab and other B cell targeted therapies for rheumatoid arthritis&quot;, section on 'Hypogammaglobulinemia and infection'</a>.)</p><p>Infusion reactions are a common side effect of <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> therapy. Deep venous thrombosis, pulmonary embolism, long-term hypogammaglobulinemia, and neutropenia have also been reported in patients treated with rituximab for pemphigus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"topic.htm?path=rituximab-and-other-b-cell-targeted-therapies-for-rheumatoid-arthritis#H17\" class=\"medical medical_review\">&quot;Rituximab and other B cell targeted therapies for rheumatoid arthritis&quot;, section on 'Other adverse effects'</a>.)</p><p class=\"headingAnchor\" id=\"H13593224\"><span class=\"h2\">Intravenous immune globulin (IVIG)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG) appears to be effective for refractory pemphigus. However, the mechanism through which IVIG improves pemphigus is not fully understood. Some authors have proposed that the infusion of IVIG may contribute to a reduction in circulating pemphigus autoantibodies by stimulating an increase in catabolism of immunoglobulins [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H341812371\"><span class=\"h3\">Efficacy and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The highest quality evidence for a beneficial therapeutic effect of IVIG in pemphigus is provided by an 85-day multicenter, randomized trial in 61 adults with glucocorticoid-resistant pemphigus (defined as a failure to respond to the equivalent of 20 mg per day or more of <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a>) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/44\" class=\"abstract_t\">44</a>]. Patients in the trial were treated with 400 <span class=\"nowrap\">mg/kg</span> of IVIG per day for five days, 200 <span class=\"nowrap\">mg/kg</span> of IVIG per day for five days, or a placebo infusion for five days. The primary endpoint in the trial was the duration of time that patients could be maintained on the treatment protocol before symptoms required additional treatment (ie, time to escape protocol). </p><p>The trial found that the time to escape protocol was significantly longer for patients in the 400 mg IVIG group compared with the patients in the placebo group [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/44\" class=\"abstract_t\">44</a>], supporting a beneficial effect of the 400 mg dose of IVIG. The difference in the time to escape protocol for the 200 mg IVIG group and the placebo group was not statistically significant. Furthermore, a significant decrease in a pemphigus activity score was detected at all study observation points for patients in the 400 mg IVIG group and at all study observation points after day 15 in the 200 mg IVIG group. The pemphigus activity score did not decrease significantly at any time point in the placebo group. </p><p>Several uncontrolled studies and case series provide additional support for the use of IVIG for refractory pemphigus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/43,45-49\" class=\"abstract_t\">43,45-49</a>]. In most of the series, patients received IVIG at a dose of 2 <span class=\"nowrap\">g/kg/cycle</span> consisting of two to four consecutive treatment days, and IVIG cycles were repeated in four-week to six-week intervals. In some studies, clinical improvement following IVIG has been found to correlate with decreasing titers of desmoglein-specific IgG autoantibodies [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/43,49\" class=\"abstract_t\">43,49</a>]. Additionally, a glucocorticoid-sparing effect of adjuvant IVIG was suggested by a small retrospective study that found significant reductions in glucocorticoid requirements following treatment with adjuvant IVIG. [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/48\" class=\"abstract_t\">48</a>]. </p><p class=\"headingAnchor\" id=\"H341812364\"><span class=\"h3\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, IVIG therapy is well tolerated. Side effects are usually mild to moderate adverse events such as headache, back pain, increased blood pressure, and abdominal discomfort [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/44\" class=\"abstract_t\">44</a>]. Aseptic meningitis is a serious side effect of IVIG therapy that requires immediate termination of treatment. Anaphylaxis is a potential risk of IVIG treatment in patients with IgA deficiency. (See <a href=\"topic.htm?path=intravenous-immune-globulin-adverse-effects\" class=\"medical medical_review\">&quot;Intravenous immune globulin: Adverse effects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H36962160\"><span class=\"h2\">Immunoadsorption</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunoadsorption is a therapeutic option for pemphigus that functions through the removal of circulating autoantibodies. In contrast to plasmapheresis, which nonselectively removes plasma proteins from circulation, immunoadsorption removes circulating IgG with a very high specificity [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/50\" class=\"abstract_t\">50</a>]. The high cost of immunoadsorption limits use of this therapy. In addition, immunoadsorption for pemphigus is not available in some countries, including the United States.</p><p class=\"headingAnchor\" id=\"H36965124\"><span class=\"h3\">Efficacy and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several apheresis systems for immunoadsorption have been successfully applied in pemphigus. The most effective columns include regenerative adsorber such as protein A or synthetic ligands (eg, PGAM146, Globaffin) that have a high affinity to the Fc-portion of human IgG [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/51-54\" class=\"abstract_t\">51-54</a>]. </p><p>The efficacy of immunoadsorption for removing pemphigus autoantibodies is influenced by the adsorber utilized and treatment protocol. In one study in which protein A adsorber was utilized, levels of antibodies against desmogleins 1 and 3 were reduced by an average of 76 percent one month after the start of immunoadsorption treatment [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/51\" class=\"abstract_t\">51</a>]. Immunoadsorption is typically administered as an adjuvant to immunosuppressive therapies in short three to four day cycles that are repeated every three to four weeks [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/51-53,55\" class=\"abstract_t\">51-53,55</a>]. </p><p>Data on the clinical efficacy of immunoadsorption in pemphigus are primarily limited to small uncontrolled studies and case series [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/51-54\" class=\"abstract_t\">51-54</a>]. The initial response to treatment can be rapid, occurring within a few weeks. Long-term improvement after immunoadsorption has been reported in several case series [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/51,53\" class=\"abstract_t\">51,53</a>]. In our experience, patients with extensive skin involvement seem to benefit most from the addition of adjuvant immunoabsorption to immunosuppressive therapy. </p><p class=\"headingAnchor\" id=\"H36964247\"><span class=\"h3\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients appear to tolerate immunoadsorption well. Infrequently reported adverse effects that may be directly related to immunoadsorption therapy include hypotension, bradycardia, anaphylaxis, and sepsis from a central catheter [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/55\" class=\"abstract_t\">55</a>].</p><p class=\"headingAnchor\" id=\"H36962740\"><span class=\"h2\">Plasmapheresis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Compared with immunoadsorption, which specifically removes circulating IgG, plasmapheresis (also known as plasma exchange) nonselectively removes plasma proteins from circulation. Plasmapheresis is a more widely available therapy.</p><p>Data are limited on the efficacy of plasmapheresis in pemphigus. Although small uncontrolled studies and case reports have associated improvement in pemphigus with plasmapheresis [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/56-61\" class=\"abstract_t\">56-61</a>], a randomized trial of 40 patients in which treatment with <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> alone was compared with prednisolone plus plasmapheresis found no significant difference in efficacy [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/62\" class=\"abstract_t\">62</a>].</p><p class=\"headingAnchor\" id=\"H4171122147\"><span class=\"h2\">Cyclophosphamide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment regimens that include <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> may be useful for inducing remission in pemphigus and reducing dependence on systemic glucocorticoids [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/6\" class=\"abstract_t\">6</a>]. The beneficial effect of cyclophosphamide in pemphigus is likely related to the drug's suppressive effect on B lymphocytes and the ensuing reduction in autoantibody production [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/63\" class=\"abstract_t\">63</a>]. The adverse effect profile of cyclophosphamide contributes to restriction of its use primarily for refractory disease [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/64\" class=\"abstract_t\">64</a>]. (See <a href=\"#H3264474540\" class=\"local\">'Adverse effects'</a> below.)</p><p class=\"headingAnchor\" id=\"H2022039234\"><span class=\"h3\">Efficacy and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Similar to <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> and <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> is usually prescribed as an adjuvant to systemic glucocorticoid therapy. Treatment regimens utilized for cyclophosphamide have varied. Several series have documented high rates of successful treatment of pemphigus with a pulsed regimen of <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> and cyclophosphamide (monthly infusion of dexamethasone [100 mg for three days] and cyclophosphamide [500 mg for one day] plus daily 50 mg doses of oral cyclophosphamide in between pulsed therapy) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/65-67\" class=\"abstract_t\">65-67</a>]. However, less consistently favorable results with this regimen have also been reported [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/68\" class=\"abstract_t\">68</a>].</p><p>A glucocorticoid-sparing effect of adjuvant <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> given in a different regimen was demonstrated in a one-year randomized trial (n = 120) that compared the efficacy of four different regimens for newly diagnosed pemphigus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/6\" class=\"abstract_t\">6</a>]. Although the rate of clinical response was similar among patients treated with both <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> (2 <span class=\"nowrap\">mg/kg</span> per day followed by a taper) and cyclophosphamide (one 1000 mg intravenous dose per month for six months and every other month thereafter) and patients treated with prednisolone alone (73 and 77 percent, respectively), the cyclophosphamide group had a lower mean total dose of prednisolone (8276 mg versus 11,631 mg). Further, the glucocorticoid-sparing effects of cyclophosphamide were similar to the glucocorticoid-sparing effects of adjuvant <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> and <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil.</p><p>The effects of treatment regimens with <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> specifically on patients with refractory pemphigus have been evaluated in uncontrolled studies that have demonstrated favorable results in some patients [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/64,69\" class=\"abstract_t\">64,69</a>]. Examples include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective uncontrolled study, 23 patients with pemphigus (20 pemphigus vulgaris, 3 pemphigus foliaceus) who had disease refractory to <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> plus <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil, who could not tolerate other therapies, or who had rapidly progressive extensive disease were treated with oral <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> (2 to 2.5 <span class=\"nowrap\">mg/kg</span> of ideal body weight per day) and prednisone (1 <span class=\"nowrap\">mg/kg</span> of ideal body weight per day followed by a taper after two to three months) [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/69\" class=\"abstract_t\">69</a>]. Of note, nine patients with severe disease also received plasma exchange during the first two weeks of treatment. </p><p/><p class=\"bulletIndent1\">Complete remission (defined as the absence of lesions for at least four weeks while on treatment with <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> and less than 0.15 <span class=\"nowrap\">mg/kg</span> per day of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>) was achieved by 17 of 20 patients with pemphigus vulgaris (85 percent) and two of three patients with pemphigus foliaceus. Three patients with pemphigus vulgaris failed to respond to treatment and one patient with pemphigus foliaceus had a partial response. The median time to remission was 8.5 months for patients who did not receive plasma exchange and 8 months for those who received the additional treatment. Six of 12 patients who achieved complete remissions and subsequently discontinued treatment with cyclophosphamide relapsed within a median time of six months.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study, 21 patients with pemphigus refractory to <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a> plus <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> or <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (18 pemphigus vulgaris, 2 pemphigus foliaceus, 1 paraneoplastic pemphigus) were treated with 4 to 22 pulses of intravenous <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> (1 g per day for three consecutive days) together with 500 mg of intravenous <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> on the second day of treatment [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/64\" class=\"abstract_t\">64</a>]. Between the monthly pulse treatments, patients were given oral cyclophosphamide (50 mg per day) and prednisolone. Continuation of adjuvant therapy with other immunosuppressives (<a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil <span class=\"nowrap\">and/or</span> methotrexate) was allowed. </p><p/><p class=\"bulletIndent1\">The study found a statistically significant reduction in skin and oral disease scores after treatment. Seven patients (33 percent) achieved an excellent response (defined as quiescent disease), and a lesser degree of response was observed in an additional 13 patients. The median number of pulses given to patients who achieved an excellent response was 12 (range 6 to 19). In addition, four patients with excellent responses achieved clinical remissions (defined as complete resolution of blisters and erosions for at least six months) that lasted for six months to six years. One of these patients was able to completely discontinue treatment while the other three remained on <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil and low-dose <a href=\"topic.htm?path=prednisolone-drug-information\" class=\"drug drug_general\">prednisolone</a>.</p><p/><p>A few case reports have documented the successful use of immunoablative high-dose <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> for severe, refractory pemphigus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/70,71\" class=\"abstract_t\">70,71</a>]. However, treatment is not uniformly effective, and a disease flare within weeks after treatment has been reported in a patient [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/70\" class=\"abstract_t\">70</a>].</p><p class=\"headingAnchor\" id=\"H3264474540\"><span class=\"h3\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adverse effects of this cytotoxic drug include myelosuppression, systemic infections, urine bladder toxicity, increased malignancies, and premature gonadal failure. Patients receiving <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> should be closely monitored for adverse effects of treatment. (See <a href=\"topic.htm?path=general-toxicity-of-cyclophosphamide-in-rheumatic-diseases\" class=\"medical medical_review\">&quot;General toxicity of cyclophosphamide in rheumatic diseases&quot;</a> and <a href=\"topic.htm?path=general-principles-of-the-use-of-cyclophosphamide-in-rheumatic-diseases#H520591803\" class=\"medical medical_review\">&quot;General principles of the use of cyclophosphamide in rheumatic diseases&quot;, section on 'Monitoring of oral CYC dosing'</a>.)</p><p class=\"headingAnchor\" id=\"H36963996\"><span class=\"h1\">OTHER THERAPIES FOR PEMPHIGUS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to the major therapeutic options for the initial treatment of pemphigus vulgaris and pemphigus foliaceus and the management of refractory disease, multiple other interventions have been reported to be of benefit in small numbers of patients. Examples include topical <a href=\"topic.htm?path=pimecrolimus-drug-information\" class=\"drug drug_general\">pimecrolimus</a> [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/72\" class=\"abstract_t\">72</a>], topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/73\" class=\"abstract_t\">73</a>], <a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">sulfasalazine</a> with <a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">pentoxifylline</a>, gold [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/74\" class=\"abstract_t\">74</a>], tetracyclines with or without <a href=\"topic.htm?path=nicotinamide-niacinamide-drug-information\" class=\"drug drug_general\">nicotinamide</a> [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/75\" class=\"abstract_t\">75</a>], <a href=\"topic.htm?path=chlorambucil-drug-information\" class=\"drug drug_general\">chlorambucil</a>, mizoribine [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/76\" class=\"abstract_t\">76</a>], and subcutaneous veltuzumab [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/77\" class=\"abstract_t\">77</a>]. </p><p>Although case reports have suggested benefit of the biologic TNF-alpha inhibitors <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> and <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> in the treatment of pemphigus [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/78-82\" class=\"abstract_t\">78-82</a>], a small randomized trial that compared combination therapy with infliximab and <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> to treatment with prednisone alone in 20 patients with pemphigus vulgaris found only non-statistically significant trends towards better results with the addition of infliximab therapy [<a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/83\" class=\"abstract_t\">83</a>]. The small size of the trial was a limiting factor; larger trials might clarify the effects of infliximab therapy.</p><p class=\"headingAnchor\" id=\"H13593245\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening disorders. First-line treatment for these diseases consists of a systemic glucocorticoid with or without an adjuvant immunosuppressant, such as <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> or <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil. (See <a href=\"#H13593189\" class=\"local\">'Overview'</a> above and <a href=\"topic.htm?path=initial-management-of-pemphigus-vulgaris-and-pemphigus-foliaceus\" class=\"medical medical_review\">&quot;Initial management of pemphigus vulgaris and pemphigus foliaceus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who do not respond sufficiently to therapies used for the initial management of this disease may benefit from other interventions, such as <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> (IVIG), immunoadsorption, plasmapheresis, and <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>. (See <a href=\"#H36962895\" class=\"local\">'Treatment options'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Due to a lack of high-quality comparative trials, data are insufficient for definitive conclusions on the relative efficacies of therapies for refractory pemphigus. Factors such as patient tolerance for specific treatments and treatment availability influence treatment selection. (See <a href=\"#H36962895\" class=\"local\">'Treatment options'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/1\" class=\"nounderline abstract_t\">Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; :CD006263.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/2\" class=\"nounderline abstract_t\">Mimouni D, Nousari CH, Cummins DL, et al. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003; 49:1059.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/3\" class=\"nounderline abstract_t\">Harman KE, Albert S, Black MM, British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149:926.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/4\" class=\"nounderline abstract_t\">Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58:1043.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/5\" class=\"nounderline abstract_t\">Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42:422.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/6\" class=\"nounderline abstract_t\">Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57:622.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/7\" class=\"nounderline abstract_t\">Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130:2041.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/8\" class=\"nounderline abstract_t\">Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/9\" class=\"nounderline abstract_t\">Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64:903.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/10\" class=\"nounderline abstract_t\">Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 2009; 129:289.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/11\" class=\"nounderline abstract_t\">Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173:683.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/12\" class=\"nounderline abstract_t\">Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6:366.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/13\" class=\"nounderline abstract_t\">Arin MJ, Hunzelmann N. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update. Eur J Dermatol 2005; 15:224.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/14\" class=\"nounderline abstract_t\">Pf&uuml;tze M, Eming R, Kneisel A, et al. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 2009; 218:237.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/15\" class=\"nounderline abstract_t\">Nagel A, Podstawa E, Eickmann M, et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009; 129:2202.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/16\" class=\"nounderline abstract_t\">Eming R, Nagel A, Wolff-Franke S, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008; 128:2850.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/17\" class=\"nounderline abstract_t\">Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008; 128:2859.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/18\" class=\"nounderline abstract_t\">Borradori L, Lombardi T, Samson J, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001; 137:269.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/19\" class=\"nounderline abstract_t\">Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001; 66:142.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/20\" class=\"nounderline abstract_t\">Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges 2012; 10:727.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/21\" class=\"nounderline abstract_t\">Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb) 2012; 2:17.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/22\" class=\"nounderline abstract_t\">Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 2012; 148:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/23\" class=\"nounderline abstract_t\">Leshem YA, Hodak E, David M, et al. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol 2013; 68:404.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/24\" class=\"nounderline abstract_t\">Matsukura S, Knowles SR, Walsh S, Shear NH. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Arch Dermatol 2012; 148:734.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/25\" class=\"nounderline abstract_t\">Horv&aacute;th B, Huizinga J, Pas HH, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012; 166:405.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/26\" class=\"nounderline abstract_t\">Heelan K, Al-Mohammedi F, Smith MJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol 2014; 150:703.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/27\" class=\"nounderline abstract_t\">Cianchini G, Lupi F, Masini C, et al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol 2012; 67:617.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/28\" class=\"nounderline abstract_t\">Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357:545.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/29\" class=\"nounderline abstract_t\">Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011; 165:646.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/30\" class=\"nounderline abstract_t\">Gregoriou S, Giatrakou S, Theodoropoulos K, et al. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial. Dermatology 2014; 228:158.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/31\" class=\"nounderline abstract_t\">Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol 2014; 170:1341.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/32\" class=\"nounderline abstract_t\">Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol 2015; 29:777.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/33\" class=\"nounderline abstract_t\">Vinay K, Kanwar AJ, Mittal A, et al. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris. JAMA Dermatol 2015; 151:878.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/34\" class=\"nounderline abstract_t\">Vinay K, Kanwar AJ, Sawatkar GU, et al. Successful use of rituximab in the treatment of&nbsp;childhood and juvenile pemphigus. J Am Acad Dermatol 2014; 71:669.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/35\" class=\"nounderline abstract_t\">Kanwar AJ, Sawatkar GU, Vinay K, Hashimoto T. Childhood pemphigus vulgaris successfully treated with rituximab. Indian J Dermatol Venereol Leprol 2012; 78:632.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/36\" class=\"nounderline abstract_t\">Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355:1772.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/37\" class=\"nounderline abstract_t\">Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012; 166:154.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/38\" class=\"nounderline abstract_t\">Behzad M, M&ouml;bs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012; 166:844.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/39\" class=\"nounderline abstract_t\">Shimanovich I, Nitschke M, Rose C, et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158:382.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/40\" class=\"nounderline abstract_t\">Ahmed AR, Kaveri S, Spigelman Z. Long-Term Remissions in Recalcitrant Pemphigus Vulgaris. N Engl J Med 2015; 373:2693.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/41\" class=\"nounderline abstract_t\">Chakraborty S, Tarantolo SR, Treves J, et al. Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab. Case Rep Oncol 2011; 4:136.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/42\" class=\"nounderline abstract_t\">Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68:1156.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/43\" class=\"nounderline abstract_t\">Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol 2008; 58:796.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/44\" class=\"nounderline abstract_t\">Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60:595.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/45\" class=\"nounderline abstract_t\">Herzog S, Schmidt E, Goebeler M, et al. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84:48.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/46\" class=\"nounderline abstract_t\">Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 2013; 93:346.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/47\" class=\"nounderline abstract_t\">Bystryn JC, Rudolph JL. IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it. J Invest Dermatol 2005; 125:1093.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/48\" class=\"nounderline abstract_t\">Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138:1158.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/49\" class=\"nounderline abstract_t\">Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol 2008; 144:1621.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/50\" class=\"nounderline abstract_t\">Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity 2006; 39:609.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/51\" class=\"nounderline abstract_t\">Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148:1222.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/52\" class=\"nounderline abstract_t\">L&uuml;ftl M, Stauber A, Mainka A, et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149:598.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/53\" class=\"nounderline abstract_t\">Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212:177.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/54\" class=\"nounderline abstract_t\">G&uuml;nther C, Laske J, Frind A, et al. Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorb adsorber. J Dtsch Dermatol Ges 2008; 6:661.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/55\" class=\"nounderline abstract_t\">Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302:241.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/56\" class=\"nounderline abstract_t\">Ranugha PS, Kumari R, Kartha LB, et al. Therapeutic plasma exchange as a crisis option in severe pemphigus vulgaris. Indian J Dermatol Venereol Leprol 2012; 78:508.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/57\" class=\"nounderline abstract_t\">Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978; 98:243.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/58\" class=\"nounderline abstract_t\">Roujeau JC, Andre C, Joneau Fabre M, et al. Plasma exchange in pemphigus. Uncontrolled study of ten patients. Arch Dermatol 1983; 119:215.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/59\" class=\"nounderline abstract_t\">Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22:35.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/60\" class=\"nounderline abstract_t\">S&oslash;ndergaard K, Carstens J, J&oslash;rgensen J, Zachariae H. The steroid-sparing effect of long-term plasmapheresis in pemphigus. Acta Derm Venereol 1995; 75:150.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/61\" class=\"nounderline abstract_t\">Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000; 43:1058.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/62\" class=\"nounderline abstract_t\">Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988; 124:1659.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/63\" class=\"nounderline abstract_t\">Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987; 79:1082.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/64\" class=\"nounderline abstract_t\">Saha M, Powell AM, Bhogal B, et al. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus. Br J Dermatol 2010; 162:790.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/65\" class=\"nounderline abstract_t\">Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34:875.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/66\" class=\"nounderline abstract_t\">Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990; 29:371.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/67\" class=\"nounderline abstract_t\">Sacchidanand S, Hiremath NC, Natraj HV, et al. Dexamethasone-cyclophosphamide pulse therapy for autoimmune-vesiculobullous disorders at Victoria hospital, Bangalore. Dermatol Online J 2003; 9:2.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/68\" class=\"nounderline abstract_t\">Rose E, Wever S, Zilliken D, et al. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges 2005; 3:200.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/69\" class=\"nounderline abstract_t\">Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003; 49:276.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/70\" class=\"nounderline abstract_t\">Nousari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003; 49:148.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/71\" class=\"nounderline abstract_t\">Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43:1065.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/72\" class=\"nounderline abstract_t\">Iraji F, Asilian A, Siadat AH. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol 2010; 9:684.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/73\" class=\"nounderline abstract_t\">Cohen SN, Lim RP, Paul CJ, Abdullah A. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol 2006; 45:1379.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/74\" class=\"nounderline abstract_t\">Salomon D, Saurat JH. Oral gold therapy (Auranofin) in pemphigus vulgaris. Dermatologica 1986; 172:310.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/75\" class=\"nounderline abstract_t\">Chen S, Lu X, Zhou G. Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline. Int J Dermatol 2003; 42:981.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/76\" class=\"nounderline abstract_t\">Hashimoto T. Treatment strategies for pemphigus vulgaris in Japan. Expert Opin Pharmacother 2008; 9:1519.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/77\" class=\"nounderline abstract_t\">Ellebrecht CT, Choi EJ, Allman DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol 2014; 150:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/78\" class=\"nounderline abstract_t\">Pardo J, Mercader P, Mahiques L, et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153:222.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/79\" class=\"nounderline abstract_t\">Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153:448.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/80\" class=\"nounderline abstract_t\">Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004; 74:245.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/81\" class=\"nounderline abstract_t\">Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005; 141:680.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/82\" class=\"nounderline abstract_t\">Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol 2009; 8:940.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-refractory-pemphigus-vulgaris-and-pemphigus-foliaceus/abstract/83\" class=\"nounderline abstract_t\">Hall RP 3rd, Fairley J, Woodley D, et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol 2015; 172:760.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15304 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13593245\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H13593182\" id=\"outline-link-H13593182\">INTRODUCTION</a></li><li><a href=\"#H255874776\" id=\"outline-link-H255874776\">DEFINITION</a></li><li><a href=\"#H13593189\" id=\"outline-link-H13593189\">OVERVIEW</a></li><li><a href=\"#H36962895\" id=\"outline-link-H36962895\">TREATMENT OPTIONS</a><ul><li><a href=\"#H7885644\" id=\"outline-link-H7885644\">Treatment selection</a></li><li><a href=\"#H13593210\" id=\"outline-link-H13593210\">Rituximab</a><ul><li><a href=\"#H255875039\" id=\"outline-link-H255875039\">- Efficacy and administration</a><ul><li><a href=\"#H36961921\" id=\"outline-link-H36961921\">Rheumatologic dosing</a></li><li><a href=\"#H2495368859\" id=\"outline-link-H2495368859\">Lymphoma dosing</a></li><li><a href=\"#H36961939\" id=\"outline-link-H36961939\">Other protocols</a></li><li><a href=\"#H469929829\" id=\"outline-link-H469929829\">Children</a></li><li><a href=\"#H36961953\" id=\"outline-link-H36961953\">Combination therapy</a></li></ul></li><li><a href=\"#H341812094\" id=\"outline-link-H341812094\">- Adverse effects</a></li></ul></li><li><a href=\"#H13593224\" id=\"outline-link-H13593224\">Intravenous immune globulin (IVIG)</a><ul><li><a href=\"#H341812371\" id=\"outline-link-H341812371\">- Efficacy and administration</a></li><li><a href=\"#H341812364\" id=\"outline-link-H341812364\">- Adverse effects</a></li></ul></li><li><a href=\"#H36962160\" id=\"outline-link-H36962160\">Immunoadsorption</a><ul><li><a href=\"#H36965124\" id=\"outline-link-H36965124\">- Efficacy and administration</a></li><li><a href=\"#H36964247\" id=\"outline-link-H36964247\">- Adverse effects</a></li></ul></li><li><a href=\"#H36962740\" id=\"outline-link-H36962740\">Plasmapheresis</a></li><li><a href=\"#H4171122147\" id=\"outline-link-H4171122147\">Cyclophosphamide</a><ul><li><a href=\"#H2022039234\" id=\"outline-link-H2022039234\">- Efficacy and administration</a></li><li><a href=\"#H3264474540\" id=\"outline-link-H3264474540\">- Adverse effects</a></li></ul></li></ul></li><li><a href=\"#H36963996\" id=\"outline-link-H36963996\">OTHER THERAPIES FOR PEMPHIGUS</a></li><li><a href=\"#H13593245\" id=\"outline-link-H13593245\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-the-use-of-cyclophosphamide-in-rheumatic-diseases\" class=\"medical medical_review\">General principles of the use of cyclophosphamide in rheumatic diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-toxicity-of-cyclophosphamide-in-rheumatic-diseases\" class=\"medical medical_review\">General toxicity of cyclophosphamide in rheumatic diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-management-of-pemphigus-vulgaris-and-pemphigus-foliaceus\" class=\"medical medical_review\">Initial management of pemphigus vulgaris and pemphigus foliaceus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intravenous-immune-globulin-adverse-effects\" class=\"medical medical_review\">Intravenous immune globulin: Adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=paraneoplastic-pemphigus\" class=\"medical medical_review\">Paraneoplastic pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rituximab-and-other-b-cell-targeted-therapies-for-rheumatoid-arthritis\" class=\"medical medical_review\">Rituximab and other B cell targeted therapies for rheumatoid arthritis</a></li></ul></div></div>","javascript":null}